<?xml version="1.0"?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "http://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset>
	<article xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
		<?properties open_access?>
		<front>
			<journal-meta>
				<journal-id journal-id-type="nlm-ta">J Mol Signal</journal-id>
				<journal-title-group>
					<journal-title>Journal of Molecular Signaling</journal-title>
				</journal-title-group>
				<issn pub-type="epub">1750-2187</issn>
				<publisher>
					<publisher-name>Ubiquity Press</publisher-name>
				</publisher>
			</journal-meta>
			<article-meta>
				<article-id pub-id-type="pmid">20594350</article-id>
				<article-id pub-id-type="pmc">2904743</article-id>
				<article-id pub-id-type="publisher-id">1750-2187-5-7</article-id>
				<article-id pub-id-type="doi">10.1186/1750-2187-5-7</article-id>
				<article-categories>
					<subj-group subj-group-type="heading">
						<subject>Research Article</subject>
					</subj-group>
				</article-categories>
				<title-group>
					<article-title>A novel mechanism of cell growth regulation by Cell Cycle and
						Apoptosis Regulatory Protein (CARP)-1</article-title>
				</title-group>
				<contrib-group>
					<contrib contrib-type="author" id="A1">
						<name>
							<surname>Jiang</surname>
							<given-names>Yan</given-names>
						</name>
						<xref ref-type="aff" rid="I1">1</xref>
						<xref ref-type="aff" rid="I5">5</xref>
						<xref ref-type="aff" rid="I6">6</xref>
						<email>jiangy@Yahoo.com</email>
					</contrib>
					<contrib contrib-type="author" id="A2">
						<name>
							<surname>Puliyappadamba</surname>
							<given-names>Vineshkumar T</given-names>
						</name>
						<xref ref-type="aff" rid="I2">2</xref>
						<email>tpvinesh@gmail.com</email>
					</contrib>
					<contrib contrib-type="author" id="A3">
						<name>
							<surname>Zhang</surname>
							<given-names>Liyue</given-names>
						</name>
						<xref ref-type="aff" rid="I5">5</xref>
						<xref ref-type="aff" rid="I6">6</xref>
						<email>lyzhang59@gmail.com</email>
					</contrib>
					<contrib contrib-type="author" id="A4">
						<name>
							<surname>Wu</surname>
							<given-names>Wenjuan</given-names>
						</name>
						<xref ref-type="aff" rid="I2">2</xref>
						<email>WuW@karmanos.org</email>
					</contrib>
					<contrib contrib-type="author" id="A5">
						<name>
							<surname>Wali</surname>
							<given-names>Anil</given-names>
						</name>
						<xref ref-type="aff" rid="I2">2</xref>
						<xref ref-type="aff" rid="I3">3</xref>
						<email>walia@mail.nih.gov</email>
					</contrib>
					<contrib contrib-type="author" id="A6">
						<name>
							<surname>Yaffe</surname>
							<given-names>Michael B</given-names>
						</name>
						<xref ref-type="aff" rid="I4">4</xref>
						<email>myaffe@mit.edu</email>
					</contrib>
					<contrib contrib-type="author" id="A7">
						<name>
							<surname>Fontana</surname>
							<given-names>Joseph A</given-names>
						</name>
						<xref ref-type="aff" rid="I1">1</xref>
						<email>Joseph.fontana@va.gov</email>
					</contrib>
					<contrib contrib-type="author" corresp="yes" id="A8">
						<name>
							<surname>Rishi</surname>
							<given-names>Arun K</given-names>
						</name>
						<xref ref-type="aff" rid="I2">2</xref>
						<email>Rishia@Karmanos.org</email>
					</contrib>
				</contrib-group>
				<aff id="I1">Department of Internal Medicine, Wayne State University and John D.
					Dingell VA Medical Center, Room B4325, 4646 John R, Detroit, MI 48201, USA</aff>
				<aff id="I2">Karmanos Cancer Institute, Wayne State University and John D. Dingell
					VA Medical Center, Room B4325, 4646 John R, Detroit, MI 48201, USA</aff>
				<aff id="I3">Department of Surgery, Wayne State University, and John D. Dingell VA
					Medical Center, Room B4245, 4646 John R, Detroit, MI 48201, USA</aff>
				<aff id="I4">Biology Department, Massachusetts Institute of Technology, Cambridge,
					MA 02115, UK</aff>
				<aff id="I5">Department of Biochemistry, University of Western Ontario Schulich
					School of Medicine and Dentistry, 4th Floor Victoria Research Labs, A4-130a 800
					Commissioners Road East, London, ON N6C 2V5, UK</aff>
				<aff id="I6">Department of Obstetrics &amp; Gynecology, University of Western
					Ontario Schulich School of Medicine and Dentistry, 4th Floor Victoria Research
					Labs, A4-130a 800 Commissioners Road East, London, ON N6C 2V5, UK</aff>
				<pub-date pub-type="collection">
					<year>2010</year>
				</pub-date>
				<pub-date pub-type="epub">
					<day>1</day>
					<month>7</month>
					<year>2010</year>
				</pub-date>
				<volume>5</volume>
				<fpage>7</fpage>
				<lpage>7</lpage>
				<history>
					<date date-type="received">
						<day>11</day>
						<month>5</month>
						<year>2010</year>
					</date>
					<date date-type="accepted">
						<day>1</day>
						<month>7</month>
						<year>2010</year>
					</date>
				</history>
				<permissions>
					<copyright-statement>Copyright: &#x00A9; 2014 The Author(s)</copyright-statement>
					<copyright-year>2014</copyright-year>
					<license license-type="open-access"
						xlink:href="http://creativecommons.org/licenses/by/3.0/">
						<license-p>This is an open-access article distributed under the terms of the
							Creative Commons Attribution 3.0 Unported License (CC-BY 3.0), which permits
							unrestricted use, distribution, and reproduction in any medium, provided the
							original author and source are credited. See <uri
								xlink:href="http://creativecommons.org/licenses/by/3.0/"
								>http://creativecommons.org/licenses/by/3.0/</uri>.</license-p>
					</license>
				</permissions>
				<self-uri xlink:href="http://www.jmolecularsignaling.com/content/5/1/7"/>
				<abstract>
					<sec>
						<title>Background</title>
						<p>CARP-1/CCAR1, a perinuclear phospho-protein, regulates signaling by
							adriamycin, steroids, or growth factors. However, intracellular events
							that regulate CARP-1-dependent cell growth are not fully understood.</p>
					</sec>
					<sec>
						<title>Results</title>
						<p>Here we investigated whether CARP-1 is involved in signaling induced by
							the protein kinase A inhibitor H89. Treatments of human breast cancer
							cells with H89 resulted in apoptosis that involved enhanced CARP-1
							threonine phosphorylation and expression. Depletion of CARP-1, on the
							other hand, abrogates apoptosis induced by H89. CARP-1 binds with signal
							transducer TAZ and over-expression of TAZ inhibits apoptosis by CARP-1.
							CARP-1 (651-759) interacts with a novel, N-terminal epitope of TAZ. H89
							treatment stimulates threonine phosphorylation of CARP-1 (651-759),
							while substitution of threonine<sup>667 </sup>to alanine interferes with
							its binding with TAZ and apoptosis by H89. In addition, expression of
							wild type or CARP-1 (651-759) causes loss of c-myc expression due, in
							part, to suppression of c-myc transcription.</p>
					</sec>
					<sec>
						<title>Conclusions</title>
						<p>CARP-1 threonine<sup>667 </sup>regulates H89-dependent signaling by a
							novel pathway that involves modulation of CARP-1 interaction with TAZ
							and transcriptional down-regulation of c-myc.</p>
					</sec>
				</abstract>
			</article-meta>
		</front>
		<body>
			<sec>
				<title>Background</title>
				<p>Apoptosis is essential in maintaining tissue homeostasis in a host of conditions
					including development, wound healing, and elimination of infectious pathogens.
					Defective apoptosis is often encountered in many diseases including cancer
						[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2"
						>2</xref>]. Although, anticancer therapeutics function in part by targeting
					apoptosis pathways, development of drug resistance remains a problem and
					therefore warrants identification and exploitation of additional apoptosis
					transducers to effectively manage drug-resistant cancers. CARP-1/CCAR1 is a
					perinuclear protein that functions in regulating signaling by growth factors as
					well as chemotherapeutics such as adriamycin, etoposide, and iressa [<xref
						ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>].
					CARP-1 is a phospho-protein that is a target of phosphorylation by the
					DNA-damage induced ATM kinase [<xref ref-type="bibr" rid="B5">5</xref>], and
					serves as a key co-activator of the steroid/thyroid receptor family of
					transcription factors as well as tumor suppressor p53 [<xref ref-type="bibr"
						rid="B6">6</xref>]. Although ectopic expression of CARP-1 diminishes levels
					of cell-cycle regulatory proteins such as c-myc, cyclin B, and topoisomerase
					II&#x3B1; [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr"
						rid="B4">4</xref>], the mechanisms by which CARP-1 regulates apoptosis and
					its role in various pathways that regulate cell growth are yet to be fully
					elucidated.</p>
				<p>We previously found that CARP-1 binds with 14-3-3/stratifin [<xref
						ref-type="bibr" rid="B3">3</xref>]. 14-3-3 proteins belong to a family of
					highly conserved and ubiquitously expressed proteins that regulate
					differentiation, cell cycle progression and apoptosis signaling by binding with
					diverse intracellular proteins in a manner dependent or independent of their
					phosphorylation [<xref ref-type="bibr" rid="B7">7</xref>]. TAZ, a
					transcriptional co-activator that has a conserved WW, a coil-coil, a
					transactivation domains, as well as has a C-terminal PDZ binding motif, is a
					ligand for 14-3-3 proteins [<xref ref-type="bibr" rid="B8">8</xref>]. TAZ is a
					negative regulator of peroxisome proliferator-activated receptor
					&#x3B3;-dependent transcription, functions as a modulator of mesenchymal stem
					cell differentiation by promoting Runx-2-dependent transcription, and is
					involved in development of multiple organs [<xref ref-type="bibr" rid="B9"
						>9</xref>]. Lats kinase phosphorylates TAZ at serine 89 that in turn
					promotes its 14-3-3-mediated nuclear export with consequent inhibition of its
					transcriptional co-activation function [<xref ref-type="bibr" rid="B8"
						>8</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Since, CARP-1 is also
					a ligand of 14-3-3, the extent CARP-1 regulates signaling involving TAZ is
					unclear.</p>
				<p>Signaling by PKA has been implicated in numerous cellular processes that include
					modulation of other protein kinases, regulation of intracellular calcium and
					transcription [<xref ref-type="bibr" rid="B11">11</xref>]. H89, a compound
					characterized in vitro as a potent and selective inhibitor of PKA, is a
					competitive antagonist of ATP at its binding site on the PKA catalytic subunit
					and therefore has been extensively used to study PKA functions [<xref
						ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13"
						>13</xref>]. A number of recent studies however have identified actions of
					H89 that are independent of its effects on PKA [reviewed in [<xref
						ref-type="bibr" rid="B14">14</xref>]], suggesting likely involvement of
					multiple pathways in transducing intracellular signaling by this compound. In
					this context, a recent report revealed involvement of a nuclear hormone receptor
					co-activator, NRIF3, in regulating H89-dependent apoptosis in breast cancer
					cells [<xref ref-type="bibr" rid="B15">15</xref>]. Since CARP-1 also associates
					with components of the mediator complex to regulate expression of ER and GR
					target genes, as well as functions as a p53 co-activator to transduce apoptosis
					by chemotherapeutic adriamycin [<xref ref-type="bibr" rid="B6">6</xref>], we
					investigated whether CARP-1 was also involved in regulating cell growth
					inhibitory signaling by H89. Apoptosis signaling induced by H89 caused elevated
					threonine phosphorylation as well as expression of CARP-1, while depletion of
					CARP-1 interfered with H89 effects. H89 regulation of CARP-1 interaction with
					TAZ and consequent repression of c-myc elaborate a novel mechanism of cell
					growth inhibition.</p>
			</sec>
			<sec>
				<title>Results</title>
				<sec>
					<title>H89 induces apoptosis, CARP-1 expression and threonine phosphorylation,
						while loss of CARP-1 prevents apoptosis by H89</title>
					<p>To test whether H89 treatments induce apoptosis and the extent CARP-1 is
						involved in growth inhibitory signaling by H89, we first determined growth
						inhibition of HBC and COS-7 cells by this agent. Exposure to H89 inhibited
						cell growth (Figure <xref ref-type="fig" rid="F1">1A</xref>), in part, by
						enhancing apoptosis (Figure <xref ref-type="fig" rid="F1">1B</xref>). Since
						H89 functions as an antagonist of the PKA catalytic subunit (PKA-C), as well
						as inhibits MSK1 and ribosomal S6Kinase [<xref ref-type="bibr" rid="B14"
							>14</xref>], we next determined whether H89 signaling targeted these
						kinases to elicit cell growth inhibition. For this purpose, we knocked-down
						each of these kinases by utilizing on-target-plus Si-RNAs. Western blot
						analyses of the HBC cells transfected separately with respective Si-RNAs
						revealed a greater than 70% to almost complete loss of PKA-C&#x3B1;, S6K, or
						MSK1 expression when compared with corresponding scrambled
						Si-RNA-transfected controls, and the targeted depletion of either of these
						kinases failed to induce apoptosis (not shown). These preliminary findings
						raise the possibility that different perhaps novel signaling pathway(s) are
						targeted by H89 to inhibit cell growth.</p>
					<fig id="F1" position="float">
						<label>Figure 1</label>
						<caption>
							<p><bold>H89 attenuates cell proliferation (A) and enhances apoptosis
									(B)</bold>. Cells growing in normal serum conditions were either
								untreated (noted as 0) or treated with noted doses of H89 for
								indicated time, followed by determination of cell proliferation by
								MTT assay (panel A) or apoptosis (panel B) as in methods. Columns in
								histograms in panels A and B represent data from 3 independent
								experiments; bars, SE. Data in both panels were analyzed using a
								two-tailed Student <italic>t </italic>test. For panel A, *P and **P
								&lt; 0.0018 and 0.00002, respectively, and for panel B, *P and **P
								&lt; 0.000026 and 0.0003, respectively, compared to the
								corresponding untreated controls.</p>
						</caption>
						<graphic xlink:href="1750-2187-5-7-1.jpg"/>
					</fig>
					<p>Whether apoptosis signaling by H89 involves CARP-1 was investigated next.
						CARP-1 levels were elevated in cells that were treated with H89 or
						piceatannol (Figure <xref ref-type="fig" rid="F2">2A</xref>). Studies from
						our laboratory as well as by others have revealed that CARP-1 is a
						phosphoprotein [<xref ref-type="bibr" rid="B4">4</xref>,<xref
							ref-type="bibr" rid="B16">16</xref>]. We further investigated whether
						H89 signaling targeted CARP-1 phosphorylation. HBC cells were either
						untreated or treated with H89, and the CARP-1 protein was immunoprecipitated
						with anti-CARP-1 (&#x3B1;2) polyclonal antibodies [<xref ref-type="bibr"
							rid="B3">3</xref>], followed by western blot analysis with
						anti-phospho-tyrosine or anti-phospho-threonine antibodies. The data
						revealed that while H89 did not cause elevated tyrosine-phosphorylation of
						CARP-1, the level of threonine phosphorylated CARP-1 was elevated following
						exposure to H89 (Figure <xref ref-type="fig" rid="F2">2B</xref>). Thus, H89
						treatments cause increased CARP-1 expression as well as its threonine
						phosphorylation.</p>
					<fig id="F2" position="float">
						<label>Figure 2</label>
						<caption>
							<p><bold>H89 induces CARP-1 expression (A) and threonine phosphorylation
									(B), and depletion of CARP-1 abrogates apoptosis by H89
									(C)</bold>. In panel A, the cells were treated with noted dose
								of H89 or piceatannol for indicated time periods. Approximately 100
								&#x3BC;g of respective protein lysates were electrophoresed on 10%
								SDS-PAGE, followed by western immunoblotting. The membranes were
								first probed with anti-CARP-1 (&#x3B1;2) antibody [<xref
									ref-type="bibr" rid="B3">3</xref>], followed by probing with
								anti-actin antibody to assess loading. In panel B, cells were either
								untreated (Control) or treated with H89 for indicated dose and time,
								and cell lysates were prepared. In lanes 2 and 3,
								co-immunoprecipitation using noted antibodies and 1000 &#x3BC;g
								protein lysate was carried out prior to western blotting. In lane 1,
								100 &#x3BC;g protein lysate was analyzed along with
								immunoprecipitates on 10% SDS-PAGE followed by immunoblotting with
								anti-phospho-tyrosine or anti-phospho-threonine antibodies. In panel
								C, HBC cells expressing normal (indicated as CARP-1 antisense
								sublines 1, 4) or 50% reduced CARP-1 (indicated as sublines 9, 10)
								were either untreated or treated with noted time and dose of H89,
								and apoptosis determined as in figure 1D. Columns in histogram
								represent data from 3 independent experiments; bars, SE.</p>
						</caption>
						<graphic xlink:href="1750-2187-5-7-2.jpg"/>
					</fig>
					<p>The role of CARP-1 in regulating H89-dependent apoptosis was further examined
						by utilizing multiple MDA-MB-468 HBC sublines that stably express CARP-1
						antisense as in methods. Wild-type HBC cells or CARP-1 antisense transfected
						sublines 1, 4, 9, and 10 were either untreated or treated with H89, and cell
						lysates analyzed for apoptosis as in methods. As shown in Figure <xref
							ref-type="fig" rid="F2">2C</xref>, H89-dependent apoptosis was inhibited
						in cells that had reduced levels of CARP-1 (sublines 9, 10) when compared to
						those with normal levels of CARP-1 (wild-type, and sublines 1, 4). Taken
						together, these results demonstrate that H89-dependent inhibition of HBC
						cell growth is likely independent of its targeting the PKA, S6K, or MSK1
						kinases, while involves elevated threonine phosphorylation and expression of
						CARP-1. Moreover, since depletion of CARP-1 interferes with apoptosis by
						H89, our data further underscore an important role for CARP-1 in signaling
						by H89.</p>
				</sec>
				<sec>
					<title>CARP-1 interacts with signal transducer TAZ, and expression of TAZ
						inhibits CARP-1-dependent apoptosis</title>
					<p>We have previously noted that expression of 14-3-3/stratifin interferes with
						apoptosis by CARP-1, and that CARP-1 interacts with 14-3-3/stratifin [<xref
							ref-type="bibr" rid="B3">3</xref>]. Moreover, 14-3-3 was also found to
						bind with TAZ protein in a manner dependent on TAZ serine phosphorylation
							[<xref ref-type="bibr" rid="B8">8</xref>]. Together with the available
						GenBank database information indicating CARP-1 as a TAZ-binding protein, we
						speculated that CARP-1 may be part of a multi-protein cytoplasmic complex,
						and that CARP-1 interactions with 14-3-3 and/or TAZ regulate signaling for
						cell growth. To test this possibility, we investigated whether CARP-1
						interacts with TAZ, the molecular basis of their interaction and the extent
						these interaction regulates apoptosis. In the first instance, the cell
						lysates derived from MDA-MB-468 and SKBR-3 breast cancer cells were
						subjected to immunoprecipitation with anti-CARP-1 (&#x3B1;2) polyclonal
						antibodies [<xref ref-type="bibr" rid="B3">3</xref>] followed by western
						immunoblotting with anti-TAZ antibodies. As shown in figure <xref
							ref-type="fig" rid="F3">3A</xref>, TAZ protein was detected in
						precipitates derived from anti-CARP-1 antibodies but not from anti-Gst-tag
						antibodies, suggesting specific interaction between cellular CARP-1 and TAZ
						proteins. We further ascertained CARP-1 interaction with TAZ by utilizing
						HCT-116 colon cancer cells that stably express myc-His-tagged wild-type
						CARP-1. These cells were transfected with plasmids encoding flag-tagged
						wild-type TAZ (pEF-TAZ-N-Flag) or mutant TAZ proteins (pEF-TAZ(-4)-N-Flag
						and pEF-TAZ(S89A)-N-Flag that encode TAZ lacking PDZ binding and serine
						phosphorylation sites, respectively). The TAZ proteins from respective cell
						lysates were immunoprecipitated with anti-Flag-tag or anti-Gst-tag
						antibodies, and the immunoprecipitates subjected to western blot analysis
						with anti-myc-tag antibody. The data revealed the presence of CARP-1 in the
						immunoprecipitates derived from anti-Flag-tag (lanes 2, 4, and 6) but not
						from anti-Gst-tag (lanes 1, 3, and 5) antibodies (Figure <xref
							ref-type="fig" rid="F3">3B</xref>), suggesting that CARP-1 binding with
						TAZ does not require the PDZ motif or serine at position 89 of TAZ. Whether
						TAZ plays a role in CARP-1-dependent apoptosis was investigated next. HBC
						cells were transfected with vector plasmid pEF1 or pEF1-TAZ-N-Flag followed
						by incubation of cells with retroviruses encoding vector or myc-His-tagged
						CARP-1 for a period of 48 h. CARP-1 transduction of cells expressing vector
						plasmid resulted in ~3-fold increase in apoptosis when compared with their
						vector transduced counterparts, whereas expression of TAZ inhibited
						apoptosis induced by CARP-1 (Figure <xref ref-type="fig" rid="F3"
						>3C</xref>). Since TAZ shuttles between cytoplasmic and nuclear compartments
							[<xref ref-type="bibr" rid="B8">8</xref>] and CARP-1 is a perinuclear
						protein [<xref ref-type="bibr" rid="B3">3</xref>], for their binding to
						occur, we ascertained the extent the two proteins co-localize. To address
						this issue, the COS-7 cells were transfected with a combination of plasmids
						encoding Flag-tagged wild-type TAZ and myc-His-tagged wild-type CARP-1,
						followed by immunocytochemical detection of fluorescently-labelled
						respective tagged proteins. As shown in Figure <xref ref-type="fig" rid="F3"
							>3D</xref>, both the proteins localized predominantly in the cytoplasmic
						compartment with punctuate nuclear presence.</p>
					<fig id="F3" position="float">
						<label>Figure 3</label>
						<caption>
							<p><bold>CARP-1 interacts with TAZ (A, B), TAZ expression interferes
									with CARP-1-dependent apoptosis (C), and CARP-1 and TAZ
									co-localize in cytoplasmic/perinuclear region (D)</bold>. For
								CARP-1 binding with TAZ, Breast cancer cells (panel A) or HCT-116
								colon cancer cells expressing myc-His-tagged wild-type CARP-1 (panel
								B) were utilized. In panel B, the cells were transfected with
								plasmids encoding wild-type or mutant TAZ proteins as indicated,
								prior to generating cell lysates. The cell lysates were then
								utilized for immunoprecipitation and western blotting using noted
								antibodies essentially as in figure 2C. In panel C, cells were
								transfected with plasmids encoding vector or wild-type TAZ followed
								by their transduction with indicated retroviruses expressing vector
								or wild-type CARP-1 as detailed in methods. The apoptosis levels
								were assessed by determining the acridine orange-positive cells as
								described before [<xref ref-type="bibr" rid="B4">4</xref>]. Columns
								in histogram represent data from 3 independent experiments; bars,
								SE. In panel D, the cells were transfected with a combination of
								plasmids encoding myc-His-tagged wild-type CARP-1 and flag-tagged
								wild-type TAZ proteins, followed by their fluorescent labeling and
								photography as described in methods.</p>
						</caption>
						<graphic xlink:href="1750-2187-5-7-3.jpg"/>
					</fig>
					<p>To map TAZ-interacting domain of CARP-1, cells were transfected with plasmid
						encoding flag tagged TAZ in combination with the vector plasmid or
						recombinant plasmids encoding various myc-His-tagged CARP-1 mutants that
						have been described before [<xref ref-type="bibr" rid="B4">4</xref>]. Cell
						lysates were utilized to immunoprecipitate CARP-1 proteins using
						anti-myc-tag antibodies followed by western blotting in conjunction with
						anti-flag tag antibody. The data revealed that TAZ-interacting epitope is
						present within CARP-1 amino acids 651-759 (Additional file <xref
							ref-type="supplementary-material" rid="S1">1A</xref>). Similar
						experimental strategy was utilized to map CARP-1-interacting epitope of TAZ
						by expressing myc-His-tagged CARP-1 (651-759) mutant in combination with
						various plasmids encoding gst-tagged TAZ proteins. We found that CARP-1
						interacted with a novel epitope within the N-terminal of TAZ, and that TAZ
						serine 89, WW, PDZ or coiled-coil motifs were not involved in its binding
						with CARP-1 (Additional file <xref ref-type="supplementary-material"
							rid="S1">1B</xref>). Our mapping studies are summarized in figure <xref
							ref-type="fig" rid="F4">4</xref>, and together with the data in figures
							<xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3"
							>3</xref> demonstrate that novel motifs of CARP-1 and TAZ are involved
						in their binding, and that TAZ expression interefers with apoptosis
						signaling by CARP-1.</p>
					<fig id="F4" position="float">
						<label>Figure 4</label>
						<caption>
							<p><bold>CARP-1 (651-759) binds with TAZ (1-120)</bold>. Schematic
								diagram of CARP-1 (WT and its various mutants; Left Box) and TAZ (WT
								and its mutants; Right Box) constructs that were utilized to map
								minimal epitopes for their interaction. All CARP-1 proteins have myc
								and 6 &#xD7; His epitopes at their carboxyl termini. All the TAZ
								proteins, with the exception of 1-120, 1-164, and 165-395, harbored
								flag epitope at their amino termini, while TAZ 1-120 and its 1-164
								and 165-395 mutants had Gst epitope at their amino termini. Positive
								interactions are indicated by + and loss/absence of interaction is
								denoted by -.</p>
						</caption>
						<graphic xlink:href="1750-2187-5-7-4.jpg"/>
					</fig>
				</sec>
				<sec>
					<title>CARP-1 threonine at position 667 is a target of H89-dependent apoptosis
						signaling</title>
					<p>To define mechanisms of H89-dependent apoptosis, we first determined whether
						TAZ-interacting CARP-1 (651-759) mutant is a target of H89 signaling. To
						address this issue, cells expressing myc-His-tagged CARP-1 (651-759) protein
						were either untreated or treated with H89. The protein complex was
						immunoprecipitated with anti-phospho-threonine antibodies, followed by
						western blotting with anti-myc-tag antibodies. H89 induced threonine
						phosphorylation of CARP-1 (651-759) protein when compared with the untreated
						control (Figure <xref ref-type="fig" rid="F5">5A</xref>) indicating that H89
						signaling targets threonine residue(s) within CARP-1 (651-759) protein.
						Since CARP-1 (651-759) mutant also harbors TAZ-binding epitope (figure <xref
							ref-type="fig" rid="F4">4</xref>), we next determined whether threonine
						phosphorylation of CARP-1 (651-759) regulates CARP-1 binding with TAZ. On
						the basis of Prosite database analysis [<xref ref-type="bibr" rid="B17"
							>17</xref>] that predicted CARP-1 threonine<sup>667 </sup>as a high
						probability phosphorylation site, we generated additional constructs for
						expression of CARP-1 (651-759) protein with threonine<sup>667
						</sup>substituted to either alanine (T667A) or aspartate (T667D) as detailed
						in methods. Cells expressing Gst-TAZ (1-120) in combination with
						myc-His-tagged CARP-1 (651-759), CARP-1 (651-759<sup>T667A</sup>), or CARP-1
							(651-759<sup>T667D</sup>) proteins were utilized to analyze protein
						complexes that were immunoprecipitated with anti-Gst-tag antibodies followed
						by western blotting with anti-myc-tag antibodies. The data revealed that TAZ
						binding with CARP-1 (651-759<sup>T667A</sup>) protein was attenuated (Figure
							<xref ref-type="fig" rid="F5">5B</xref>, lane 3). T667D substitution in
						CARP-1 (651-759) protein, on the other hand, enhanced its binding with TAZ
						(Figure <xref ref-type="fig" rid="F5">5B</xref>, lane 4) when compared with
						binding of CARP-1 (651-759) with TAZ. Since substitution of
						phospho-threonine or phospho-serine residue(s) to aspartate often mimics
						phosphorylated state of a protein, it is likely that threonine<sup>667
						</sup>to aspartate change allows a threonine phosphorylated conformation of
						CARP-1 (651-759), and favors its binding with TAZ.</p>
					<fig id="F5" position="float">
						<label>Figure 5</label>
						<caption>
							<p><bold>CARP-1 threonine<sup>667 </sup>is a target of H89 signaling,
									regulates CARP-1-TAZ binding, and CARP-1-dependent
									apoptosis</bold>. (<bold>A</bold>) Cells transfected with
								plasmid encoding myc-His-tagged CARP-1 (651-759) mutant were either
								untreated (Control) or treated with H89 for indicated dose and time,
								and cell lysates were prepared, and protein lysate subjected to
								immunoprecipitation using phospho-theronine antibodies (noted as
								P-Thr Ab), and protein lysate (100 &#x3BC;g, lane indicated with -)
								along with immunoprecipitates (lanes indicated with +) analyzed by
								western blotting with anti-myc-tag antibody. (<bold>B</bold>) Cells
								were transfected with plasmid encoding flag-tagged TAZ (1-120)
								mutant [indicated as pEBG-TAZ (1-120)] in combination with plasmids
								expressing noted myc-His-tagged CARP-1 mutant proteins. The cell
								lysates in lanes 2, 3, and 4 were subjected to immunoprecipitation
								using anti-Gst tag antibodies essentially as in figure 4B. Protein
								lysate and immunoprecipitates analyzed by western blotting as in
								panel A. Presence of CARP-1 (651-759) proteins is indicated on the
								left side of each panel. (<bold>C) </bold>Cells were either
								untransduced (Control), or transduced with retroviruses expressing
								vector or myc-His-tagged CARP-1 mutants. (<bold>D</bold>) Cells were
								transduced with retroviruses encoding vector plasmid or wild-type
								TAZ followed by treatments with H89 for noted dose and time. Protein
								lysates in both panels C and D were assayed for apoptosis
								essentially as in figure 1D. Columns in histograms represent data
								from 2 independent experiments; bars, SE. Data in panels C and D
								were analyzed using a two-tailed Student <italic>t </italic>test.
								For panel C, *P &lt; 0.005, while for panel D, *P &lt; 0.0087,
								compared to the corresponding vector controls.</p>
						</caption>
						<graphic xlink:href="1750-2187-5-7-5.jpg"/>
					</fig>
					<p>Whether CARP-1 threonine<sup>667 </sup>regulates apoptosis signaling was
						investigated next. Cells were either untransduced or transduced with viruses
						encoding vector, myc-His-CARP-1 (651-759), or myc-His-CARP-1
							(651-759<sup>T667A</sup>) proteins for 48 h followed by apoptosis
						determination as in methods. The cells transduced with myc-His-CARP-1
						(651-759) displayed significantly enhanced apoptosis when compared to the
						apoptosis noted for their vector-transduced or untransduced counterparts
						(Figure <xref ref-type="fig" rid="F5">5C</xref>). Expression of
						myc-His-CARP-1 (651-759<sup>T667A</sup>) protein, on the other hand,
						resulted in lower levels of apoptosis when compared to apoptosis noted in
						myc-His-CARP-1 (651-759) transduced cells (Figure <xref ref-type="fig"
							rid="F5">5C</xref>). These findings suggest that expression of
						myc-His-CARP-1 (651-759) protein, like wild-type or CARP-1 (603-898) mutant
							[<xref ref-type="bibr" rid="B4">4</xref>] promotes apoptosis while T667A
						substitution interferes with this function.</p>
					<p>Since H89 treatments caused elevated CARP-1 expression and apoptosis, while
						CARP-1 interacts with TAZ, and TAZ regulates CARP-1-dependent apoptosis
						(figures <xref ref-type="fig" rid="F2">2</xref>, <xref ref-type="fig"
							rid="F3">3</xref>), we wished to determine whether and to what extent
						TAZ regulates H89-dependent apoptosis. For this experiment, we first
						transduced the HBC cells with viruses encoding vector or mouse TAZ (wt)
						protein for a period of 12 h. The cells were then either untreated or
						treated with H89 for additional 48 h, followed by determination of
						apoptosis. Although, exposure to H89 caused statistically significant
						increase in apoptosis of vector transduced cells, it failed to promote
						apoptosis in TAZ-transduced cells (Figure <xref ref-type="fig" rid="F5"
							>5D</xref>). These findings suggest that TAZ interferes with apoptosis
						signaling by H89, and together with the data in figures <xref ref-type="fig"
							rid="F2">2</xref>, <xref ref-type="fig" rid="F3">3</xref> and <xref
							ref-type="fig" rid="F4">4</xref> indicate that CARP-1 threonine
						phosphorylation following H89 treatment promotes TAZ sequestration by CARP-1
						that, in part, contributes to CARP-1-dependent growth suppression by
						H89.</p>
				</sec>
				<sec>
					<title>Apoptosis signaling by H89 or CARP-1 target c-myc expression</title>
					<p>Since we previously found that CARP-1 negatively regulates c-myc expression
							[<xref ref-type="bibr" rid="B3">3</xref>], we wished to determine
						whether and to what extent expression of cell proliferation regulatory genes
						such as c-myc and topoisomerase II&#x3B1; are a target of CARP-1-mediated
						H89 signaling and the mechanisms involved therein. To test this possibility,
						we first determined whether expression of c-myc and topoisomerase II&#x3B1;
						is inhibited by CARP-1 and its TAZ-interacting mutants. Expression of
						wild-type CARP-1 or its TAZ-interacting mutants {CARP-1 (603-898) or CARP-1
						(651-759) proteins} resulted in reduced levels of c-myc as well as
						topoisomerase II&#x3B1; when compared with their vector-transduced
						counterparts (Figure <xref ref-type="fig" rid="F6">6A</xref>). Furthermore,
						treatments with H89 or piceatannol also resulted in diminished c-myc
						expression in HBC cells when compared with their untreated counterparts
						(Figure <xref ref-type="fig" rid="F6">6B</xref>). Since, H89 causes elevated
						expression of CARP-1 and apoptosis, the findings in figure <xref
							ref-type="fig" rid="F6">6A</xref> and <xref ref-type="fig" rid="F6"
							>6B</xref> suggest that cell growth inhibition following H89 treatments
						are due, in part, to CARP-1-dependent loss of cell growth promoting factors
						such as c-myc.</p>
					<fig id="F6" position="float">
						<label>Figure 6</label>
						<caption>
							<p><bold>Expression of CARP-1 (A) or H89 treatment (B) causes reduced
									c-myc levels, in part by suppressing c-myc transcription
									(C)</bold>. Cells were transduced with retroviruses encoding
								vector or CARP-1 proteins as indicated in panel A. For panel B, HBC
								cells were either untreated or treated with indicated doses of H89
								or piceatannol. Approximately 100 &#x3BC;g of respective protein
								lysate was analyzed by SDS-PAGE, followed by western immunoblotting
								with either anti c-myc or topoisomerase II&#x3B1; antibodies
								essentially as in methods. The membrane was subsequently probed with
								anti-actin antibody to assess loading. Presence of c-myc,
								topoisomerase II&#x3B1; and actin proteins is denoted on the left
								side of each panel. In panel C, HBC cells were transfected with
								indicated c-myc promoter-luciferase reporter plasmid. The cells were
								either untreated (Control) or treated with H89. In addition, the HBC
								cells were separately transfected with luciferase reporter plasmids
								having full length c-myc promoter or its various deletions, followed
								by their transduction with retroviruses encoding vector or CARP-1
								protein. The cell lysates were analyzed for luciferase reporter
								activities as in methods. Columns in the histograms represent means
								of two independent experiments; bars, SE. Data were analyzed using a
								two-tailed Student <italic>t </italic>test. For top left histogram,
								*P &lt; 0.044, compared to the corresponding control, and for the
								lower histogram, *P &lt; 0.0055 and **P &lt; 0.006, compared to the
								respective vector-transduced controls. Panel D, Schematic of
								CARP-1-dependent growth suppression signaling in the presence of
								H89. = , Binding.</p>
						</caption>
						<graphic xlink:href="1750-2187-5-7-6.jpg"/>
					</fig>
					<p>In the next set of experiments, we investigated the mechanism(s) of
						H89-dependent loss of c-myc expression. Since TAZ is a transcriptional
						co-activator and CARP-1 is also a regulator of nuclear receptor complex
							[<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B8"
							>8</xref>], we first examined whether CARP-1 induction following H89
						treatment attenuates c-myc transcription. To this end, we utilized a plasmid
						where luciferase reporter is driven by a mouse c-myc promoter from positions
						-1138 to +580 relative to the P1 transcription start site [<xref
							ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19"
							>19</xref>]. As expected, significant loss of c-myc promoter activity
						was noted in H89-treated HBC cells (Figure <xref ref-type="fig" rid="F6"
							>6C</xref>, top left). The extent of CARP-1 attenuated c-myc
						transcription was further investigated by transducing c-myc
						promoter-luciferase reporter-transfected HBC cells with retroviruses
						encoding vector, wild-type CARP-1, or CARP-1 (651-759) proteins. Expression
						of wild-type CARP-1 or its TAZ-interacting 651-759 mutant caused significant
						loss of c-myc promoter activity when compared with their vector-transduced
						counterparts (Figure <xref ref-type="fig" rid="F6">6C</xref>, top right).
						Additional transfection studies revealed that CARP-1/TAZ-responsive
						element(s) is located within -140 to +310 region of the mouse c-myc promoter
						(Figure <xref ref-type="fig" rid="F6">6C</xref>, lower). Taken together,
						data in figure <xref ref-type="fig" rid="F6">6</xref> demonstrate that
						attenuation of c-myc expression by H89 or CARP-1 is accomplished, in part,
						by transcriptional down-regulation of c-myc, and contributes to the growth
						suppressing effects of CARP-1 and H89.</p>
				</sec>
			</sec>
			<sec>
				<title>Discussion</title>
				<p>We previously reported identification and characterization of CARP-1/CCAR1, a
					peri-nuclear phospho-protein that mediates apoptosis signaling by diverse agents
					including adriamycin and inhibitors of EGFRs [<xref ref-type="bibr" rid="B3"
						>3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. The micro-array-based
					approach revealed that CARP-1-dependent cell growth inhibition involves cell
					cycle regulatory proteins such as c-Myc and cyclin B1 [<xref ref-type="bibr"
						rid="B3">3</xref>]. Since attenuation of PKA often inhibits cell growth we
					wished to investigate whether CARP-1 was involved in this signaling. Our studies
					revealed that H89, a commonly utilized pharmacologic inhibitor of PKA-C&#x3B1;,
					inhibited cell growth in part by inducing apoptosis. The fact that a number of
					recent studies have implicated H89 as an inhibitor of other kinases such as the
					MSK1 and the ribosomal S6Kinase [reviewed in ref [<xref ref-type="bibr"
						rid="B14">14</xref>]], we first clarified whether apoptosis induction by H89
					involved its targeting of PKA-C&#x3B1;, MSK1, or S6Kinases. Surprisingly,
					Si-RNA-dependent knock-down of either of these kinases failed to induce
					apoptosis in HBC cells. Furthermore, HBC cells that were treated with various
					doses of R<sub>p</sub>-cAMPS, a competitive antagonist of the cyclic
					nucleotide-binding domain on PKA, over a range of time periods also failed to
					stimulate apoptosis (not shown). Our Si-RNA-based experiments therefore suggest
					that H89 likely inhibits cell growth independent of its targeting of the
					PKA-C&#x3B1;, MSK1, or S6Kinases and may point to additional cell growth
					inhibitory mechanisms utilized by this agent. The fact that CARP-1 was involved
					in transducing H89 signaling as noted in our current studies, we propose that
					CARP-1-dependent H89 inhibition of HBC cell growth is a novel pathway (Figure
						<xref ref-type="fig" rid="F6">6D</xref>).</p>
				<p>CARP-1 and its mutants suppress cell growth in part by activating intrinsic
					apoptosis pathway [<xref ref-type="bibr" rid="B4">4</xref>]. Moreover, CARP-1
					interacted with cytoplasmic signaling transducer 14-3-3/Stratifin protein, while
					over-expression of stratifin interfered with CARP-1-dependent apoptosis [<xref
						ref-type="bibr" rid="B3">3</xref>]. An array of cell growth regulators such
					as Raf, PI-3 kinase, MEKK, BAD, ASK-1, cdc25, CDK25, p53, FKHRL, and TAZ serve
					as substrates for binding with 14-3-3 proteins. TAZ, in particular, interacts
					with 14-3-3 protein in a phsophorylation-dependent manner, and in the light of
					our data demonstrating CARP-1 binding with TAZ, and the fact that overexpression
					of TAZ attenuates CARP-1-dependent apoptosis (figures <xref ref-type="fig"
						rid="F4">4</xref> and <xref ref-type="fig" rid="F5">5</xref>), suggests for
					existence of a dynamic multiprotein cytoplasmic complex that functions to
					regulate cell growth. This complex is a target of phosphorylation signaling by
					H89 is further supported by our data in figure <xref ref-type="fig" rid="F5"
						>5</xref> showing TAZ-binding sub-domain of CARP-1 (CARP-1 651-759) is a
					target of threonine phopshorylation by H89, and that the threonine<sup>667
					</sup>regulates CARP-1 binding with TAZ and subsequent apoptosis.</p>
				<p>Since, CARP-1 has a novel serine-phosphorylation motif [<xref ref-type="bibr"
						rid="B16">16</xref>], and the fact that 14-3-3 proteins often bind to
					serine/threonine-phosphorylated residues in their target proteins [<xref
						ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21"
						>21</xref>] it is unclear whether CARP-1 interactions with 14-3-3/Stratifin
					are dependent on prior specific serine/threonine phosphorylation of CARP-1.
					CARP-1 binding with TAZ, on the other hand, is dependent on phosphorylation of
					CARP-1 threonine<sup>667 </sup>without the involvement of TAZ WW, PDZ domain
					protein binding, and 14-3-3-interacting motifs as reflected by our data in
					figure <xref ref-type="fig" rid="F4">4</xref>. Since TAZ appears to have a novel
					motif for binding with CARP-1, it is likely that TAZ mediates CARP-1
					sequestration by 14-3-3 in a manner dependent on phosphorylation of both the TAZ
					and CARP-1 proteins, in turn promoting the formation of a multiprotein
					cytoplasmic complex. The enhanced threonine phosphorylation and expression of
					CARP-1 in the presence of H89 likely favors cytoplsmic sequestration of TAZ, and
					consequently interferes with nuclear translocation and transcriptional
					co-activation function of TAZ.</p>
				<p>A range of transcription factors target specific cis-sequences within the c-myc
					promoter and enhancer region in a manner that is often dependent on the cell
					type as well as context of the signaling pathway [<xref ref-type="bibr"
						rid="B22">22</xref>]. For example, PDGF-dependent mitogenic signaling
					regulates c-Myc expression through multiple pathways that target c-myc promoter
					elements [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr"
						rid="B24">24</xref>]. The PDGF activates c-myc transcription through a JNK
					and AP-1/c-fos/c-Jun-dependent pathway that targets a canonical AP-1 consensus
					element located ~1.3 kb upstream of the P1 start site [<xref ref-type="bibr"
						rid="B23">23</xref>], while PDGF-dependent c-myc expression is also
					regulated through Rho GTPases involving a region from -157 to +500 relative to
					P1 transcription start site of c-myc promoter [<xref ref-type="bibr" rid="B24"
						>24</xref>]. In the latter case, however, the precise nature of the
					cis-trans elements remains to be elucidated. Although, TAZ is a transcriptional
					co-activator of proteins with PPXY motifs, that include a growing list of
					transcription factors such as c-Jun [<xref ref-type="bibr" rid="B8">8</xref>],
					and the fact that CARP-1-TAZ interactions following H89 treatments interfere
					with c-myc transcription (figure <xref ref-type="fig" rid="F6">6</xref>) while
					the AP-1 consensus sequences are located outside of the region targeted by H89
					or CARP-1 (see figure <xref ref-type="fig" rid="F6">6</xref>) suggest that
					H89-dependent TAZ-CARP-1 signaling is unlikely to interfere with AP-1 function.
					However, of note is the fact that the H89-responsive mouse c-myc promoter region
					(-140 to +310 relative to P1 start site, figure <xref ref-type="fig" rid="F6"
						>6</xref>) overlaps with -157 to +500 region of human c-myc promoter
					sequences that are targeted by PDGF through the Rho GTPases. Whether the two
					signaling pathways indeed share a common transcription factor(s) that target
					known and/or novel cis sequences remains to be clarified.</p>
			</sec>
			<sec>
				<title>Conclusion</title>
				<p>H89 utilizes a novel pathway to regulate HBC cell growth in a manner involving
					elevated threonine phosphorylation of CARP-1, its binding with a transcriptional
					co-activator TAZ, and repression of c-myc.</p>
			</sec>
			<sec sec-type="methods">
				<title>Methods</title>
				<sec>
					<title>Materials</title>
					<p>DMEM, Ham's F-12 medium, fetal bovine serum (FBS), and lipofectamine-based
						transfection kit were purchased from Life Technologies, Inc., Grand Island,
						NY. Piceatannol, H89, R<sub>p</sub>-cAMPS (a competitive antagonist of the
						cyclic nucleotide-binding domain on PKA), and S<sub>p</sub>-cAMPS (a
						competitive agonist of the cyclic nucleotide-binding domain on PKA) were
						obtained from Calbiochem/EMD Biosciences (San Diego, CA). The anti-PKA
						C&#x3B1;, anti-phospho-PKA C (Thr197) polyclonal antibodies, anti-MSK1,
						anti-ribosomal S-6-kinase, as well as anti-myc-tag mouse monoclonal (9B11)
						antibodies were purchased from Cell Signaling (Beverley, MA). Anti-flag M2
						and anti-c-myc (clone 67P05) monoclonal antibodies were obtained from
						Sigma-Aldrich, (St. Louis, MO) and Lab Vision (Fremont, CA), respectively.
						Anti-phospho-tyrosine and anti-phospho-serine antibodies were purchased from
						Zymed labs (San Francisco, CA), while Anti-phospho-threonine (H-2) HRP
						conjugate were from Santa Cruz Biotech (Santa Cruz, CA). Anti-topoisomerase
						II&#x3B1; mouse monoclonal (3F6) antibody was from Novacastra/Vector
						laboratories, Burlingame, CA, and anti-Gst rabbit polyclonal antibody was
						purchased from Upstate Biotech, Lake placid, NY. Phospho-enrichment beads
						were purchased from BD Biosciences (Palo Alto, CA).</p>
				</sec>
				<sec>
					<title>Recombinant plasmid constructs</title>
					<p>The construction of plasmid clone 6.1 expressing myc-His-tagged wild-type
						CARP-1 as well as clone 1.6 expressing CARP-1 antisense has been described
						before [<xref ref-type="bibr" rid="B3">3</xref>]. The plasmids
						pEF-TAZ-N-Flag, pEF-TAZ(-4)-N-Flag, and pEF-TAZ(S89A)-N-Flag that encode
						wild type or mutant TAZ proteins were as detailed before [<xref
							ref-type="bibr" rid="B8">8</xref>]. The plasmids encoding N-terminal gst
						epitope tagged wild type or mutants TAZ proteins were generated by PCR
						amplification using mouse TAZ cDNA as template followed by their cloning
						into the pEBG vector plasmid. The plasmid pEBG-TAZ (wt) encodes Gst-tagged
						wild-type TAZ, while pEBG-TAZ (1-164), pEBG-TAZ (165-395), and pEBG-TAZ
						(1-120) encode Gst-tagged truncated mouse TAZ proteins. Of note is that fact
						that the mutant TAZ (1-120) lacks the WW domain that has been implicated in
						TAZ interactions with PPXY motif of nuclear transcription factors such as
						c-Jun [<xref ref-type="bibr" rid="B8">8</xref>]. In addition, recombinant
						plasmids for expression of mutant CARP-1 proteins were generated by a
						combination of standard PCR amplification and cloning methodologies to
						generate constructs that encode CARP-1 proteins having myc and His tags
						positioned at the carboxyl termini. Constructs encoding CARP-1 (651-759)
						protein having threonine at position 667 substituted with alanine or
						aspartate were similarly generated using a combination of PCR amplification
						and cloning methods. All the recombinant plasmids were sequenced to
						ascertain validity of the cDNA inserts. The plasmids having mouse c-myc
						promoter (-1138 to +580, -426 to +580, -140 to +310, and -140 to +175
						relative to the P1 transcription site) driving luciferase reporter gene have
						been described before [<xref ref-type="bibr" rid="B18">18</xref>,<xref
							ref-type="bibr" rid="B19">19</xref>].</p>
				</sec>
				<sec>
					<title>Cell Lines and Cell Culture</title>
					<p>ER-negative, p53-negative SKBR-3, MDA-MB-468 HBC cells, and their sublines
						expressing CARP-1 antisense (Clone 1.6 sublines 1, 4, 9, and 10), as well as
						human colon cancer HCT-116 cells were cultured and maintained as detailed
						before [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr"
							rid="B19">19</xref>]. HCT-116 sublines stably expressing vector plasmid
						or myc-His-tagged wild type CARP-1 were isolated and characterized as
						described before [<xref ref-type="bibr" rid="B4">4</xref>]. Monkey kidney
						COS-7 and NIH3T3 mouse fibroblast cells were obtained from ATCC (Manassas,
						VA) and propagated per vendor's suggestions. NIH3T3 derivative PT-67 mouse
						fibroblasts were purchased from BD-Clontech (Palo Alto, CA), and generation
						and characterization of their stable isolates expressing vector pLNCX2,
						myc-His-tagged wild-type or mutant CARP-1 proteins was carried out as
						previously described [<xref ref-type="bibr" rid="B3">3</xref>,<xref
							ref-type="bibr" rid="B4">4</xref>].</p>
				</sec>
				<sec>
					<title>Luciferase assays</title>
					<p>Cells were plated either in a 60-mm dish or in a 6-well plate at a density of
						3 &#xD7; 10<sup>5 </sup>cells/ml and then co-transfected with pTK/Renilla
						Luc in combination with various c-myc-Promoter-luc constructs essentially
						following previously detailed methods [<xref ref-type="bibr" rid="B3"
							>3</xref>,<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr"
							rid="B25">25</xref>]. After 6-h incubation with plasmid DNAs, cells were
						washed three times with 1 &#xD7; PBS, co-incubated with retroviruses
						encoding vector, wild-type or mutant CARP-1 proteins, and allowed to grow in
						the appropriate culture media for additional 48 h. The cells were then
						harvested, lysed, and Renilla and firefly luciferase activities were
						measured using dual luciferase assay kit (Clontech) essentially following
						vendors guidelines.</p>
				</sec>
				<sec>
					<title>Gene Knock-down experiments</title>
					<p>CARP-1 expression was down-regulated in HBC cells by stably expressing a
						plasmid expressing CARP-1 antisense cDNA. Antisense transfected sublines 1,
						4 express normal levels, while sublines 9 and 10 express 50% reduced levels
						of CARP-1 and their characterization has been detailed before [<xref
							ref-type="bibr" rid="B3">3</xref>]. Depletion of PKA-C&#x3B1;, CARP-1,
						S6K, or MSK1 was carried out by transfecting MDA-MB-468 HBC cells with
						scrambled (non-target) or respective specific on-target Si-RNAs (Dharmacon)
						following manufacturer suggested guidelines. Seventy-two hours
						post-transfections, the cell lysates were analyzed by western immunoblotting
						in conjunction with respective antibodies essentially following the
						methodologies detailed below.</p>
				</sec>
				<sec>
					<title>Immunoprecipitation, Western Blot, Apoptosis, and Co-localization
						Assays</title>
					<p>Logarithmically growing cells were either untransfected or transfected with
						various plasmids for 24 or 48 hours followed by their lysis to prepare
						protein extracts. In certain instances cells were treated with H89. For
						immunoprecipitation aliquots of cell lysates containing 1.0 mg proteins were
						incubated with indicated antibodies and Sepharose G at 4&#xB0;C for 3 hours.
						Immunoprecipitates or the protein extracts were then analyzed by western
						blotting using indicated antibodies per the manufacturer's guidelines and
						previously published protocols [<xref ref-type="bibr" rid="B3"
							>3</xref>,<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr"
							rid="B19">19</xref>]. For enrichment of phosphorylated proteins, the
						cells were first transfected with plasmids encoding wild-type or mutant
						CARP-1 proteins, followed by treatments of cells with H89. Equal amounts (1
						mg) of cell lysates were then applied to phospho-protein enrichment columns;
						the complexes were washed and eluted following manufacturer suggested
						methodology. The enriched phospho-proteins alongwith the protein lysate from
						transfected cells were analyzed by western blotting first with anti-myc tag
						antibodies followed by reprobing with anti-phospho-tyrosine antibodies. In
						addition, cell lysates were prepared from untreated as well as treated cells
						to determine apoptosis by utilizing cell death detection ELISA kit (Roche
						Diagnostics). The net absorbances at the suggested wavelengths
							(A<sub>405</sub>nm minus A<sub>495</sub>nm) were obtained for the
						lysates derived from treated as well as untreated cells. The histograms
						indicating levels of apoptosis were generated either by plotting net
						absorbances or by calculating the "enrichment factor" as described [<xref
							ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4"
							>4</xref>]. In certain instances, cell death was measured by counting
						acridine orange-ethidium bromide stained cells [<xref ref-type="bibr"
							rid="B25">25</xref>], while viabilities of untreated and treated cells
						were also measured by utilizing LIVE/DEAD viability/cytotoxicity assay
						(Molecular Probes, Eugene, OR).</p>
					<p>COS-7 cells were transfected with plasmid expressing myc-His-tagged wild-type
						CARP-1 (CARP-1 clone 6.1; ref. [<xref ref-type="bibr" rid="B3">3</xref>]) in
						combination with plasmid expressing wild-type TAZ (pEF/mTAZ-N-Flag, ref.
							[<xref ref-type="bibr" rid="B8">8</xref>]). The cells were trypsinized,
						fixed, and permeablizied followed by incubation with a combination of
						anti-Flag tag mouse monoclonal and anti-myc tag rabbit polyclonal antibodies
						at 4&#xB0;C for overnight. The cells were washed again in 1 &#xD7; PBS for
						three times, and incubated with a combination of rhodamine conjugated
						goat-anti-rabbit and Alexa 488 conjugated goat-anti-mouse IGg for a period
						of 30 min at 37&#xB0;C. The cells were washed twice with pre-warmed 1 &#xD7;
						PBS, and coverslips were mounted with an aqueous-based anti-fade medium. The
						cell fluorescence was detected by an Olympus BX51 fluorescent microscope
						fitted with a triple DAPI/FITC/TRITC cube, and the images were captured by a
						DP70 digital camera and image acquisition software. The exposure time and
						magnification (400&#xD7;) were maintained throughout the capture of images.
						The images were subsequently analyzed by Image analysis and Adobe Photoshop
						software.</p>
				</sec>
			</sec>
			<sec>
				<title>Abbreviations</title>
				<p>CARP-1/CCAR1: Cell cycle and apoptosis regulatory protein 1/Cell division cycle
					and apoptosis regulator 1; HBC: Human breast cancer; H89:
						<italic>N</italic>-[2-(<italic>p</italic>-bromocinnamylamino)
					ethyl]-5-isoquinolinesulfonamide; TAZ: Transcriptional
						co-<underline>a</underline>ctivator of PD<underline>Z</underline> binding
					proteins; ER: estrogen receptor; GR: glucocorticoid receptor; PKA: Protein
					kinase A; R<sub>p</sub>-cAMPS: R<sub>p</sub>-adenosine-3', 5'-cyclic
					monophosphorothioate; S<sub>p</sub>-cAMPS: S<sub>p</sub>-adenosine-3', 5'-cyclic
					monophosphorothioate; PCR: Polymerase chain reaction; EGFR: epidermal growth
					factor receptor; S6K: ribosomal S6 kinase; MSK: mitogen and stress-activated
					kinase.</p>
			</sec>
			<sec>
				<title>Competing interests</title>
				<p>The authors declare that they have no competing interests.</p>
			</sec>
			<sec>
				<title>Authors' contributions</title>
				<p>YJ carried out majority of experiments including western blots,
					immunoprecipitations, apoptosis assays, transfections and luciferase assays. VTP
					and WW carried out SiRNA and some western blot experiments, respectively while
					LZ carried out CARP-1/TAZ mapping experiments to determine their interacting
					epitopes. MBY provided various mutants of TAZ, and MBY, AW and JAF participated
					in design and discussion of certain experiments. AKR subcloned various CARP-1
					mutants, and is the corresponding author responsible for experimental design and
					coordination, as well as writing of the manuscript and formatting of all the
					figures. All authors read and approved the final manuscript.</p>
			</sec>
			<sec sec-type="supplementary-material">
				<title>Supplementary Material</title>
				<supplementary-material content-type="local-data" id="S1">
					<caption>
						<title>Additional file 1</title>
						<p><bold>Supplemental Figure</bold>. CARP-1 (651-759) binds with TAZ
							(1-120). Cells were transfected with plasmid encoding flag-tagged
							wild-type TAZ in combination vector or plasmids expressing noted
							myc-His-tagged CARP-1 mutant proteins (panel A), or the indicated
							combinations of myc-His-tagged CARP-1 (651-759) and gst-tagged TAZ
							mutants (panel B). The immunoprecipitation and western blotting were
							carried out using noted antibodies essentially as in figure <xref
								ref-type="fig" rid="F3">3</xref>. In panel A, the membranes were
							subsequently probed with anti-myc-tag antibodies to assess expression of
							respective CARP-1 mutant protein.</p>
						<p><ext-link xlink:href="/article/downloadSuppFile/1750-2187-5-7/52">Click here for file</ext-link></p>
					</caption>
				</supplementary-material>
			</sec>
		</body>
		<back>
			<sec>
				<title>Acknowledgements</title>
				<p>This work was supported by The Susan G. Komen Breast Cancer Foundation (AKR), the
					medical research services of the Department of Veterans Affairs (AKR, AW), and
					by National Institutes of Health RO1 (JAF).</p>
			</sec>
			<ref-list>
				<ref id="B1">
					<element-citation publication-type="journal">
						<name>
							<surname>Zong</surname>
							<given-names>W-X</given-names>
						</name>
						<name>
							<surname>Thompson</surname>
							<given-names>CB</given-names>
						</name>
						<article-title>Necrotic death as a cell fate</article-title>
						<source>Genes &amp; Develop</source>
						<year>2006</year>
						<volume>20</volume>
						<fpage>1</fpage>
						<lpage>15</lpage>
					</element-citation>
				</ref>
				<ref id="B2">
					<element-citation publication-type="journal">
						<name>
							<surname>Nelson</surname>
							<given-names>DA</given-names>
						</name>
						<name>
							<surname>White</surname>
							<given-names>E</given-names>
						</name>
						<article-title>Exploiting different ways to die</article-title>
						<source>Genes &amp; Develop</source>
						<year>2004</year>
						<volume>18</volume>
						<fpage>1223</fpage>
						<lpage>1226</lpage>
					</element-citation>
				</ref>
				<ref id="B3">
					<element-citation publication-type="journal">
						<name>
							<surname>Rishi</surname>
							<given-names>AK</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Boyanapalli</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Wali</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Mohammad</surname>
							<given-names>RM</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Fontana</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Hatfield</surname>
							<given-names>JS</given-names>
						</name>
						<name>
							<surname>Dawson</surname>
							<given-names>MI</given-names>
						</name>
						<name>
							<surname>Majumdar</surname>
							<given-names>APN</given-names>
						</name>
						<name>
							<surname>Reichert</surname>
							<given-names>U</given-names>
						</name>
						<article-title>Identification and characterization of a cell cycle and
							apoptosis regulatory protein-1 as a novel mediator of apoptosis
							signaling by retinoid CD437</article-title>
						<source>J Biol Chem</source>
						<year>2003</year>
						<volume>278</volume>
						<fpage>33422</fpage>
						<lpage>33435</lpage>
						<pub-id pub-id-type="doi">10.1074/jbc.M303173200</pub-id>
						<pub-id pub-id-type="pmid">12816952</pub-id>
					</element-citation>
				</ref>
				<ref id="B4">
					<element-citation publication-type="journal">
						<name>
							<surname>Rishi</surname>
							<given-names>AK</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Yu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Jiang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Nautiyal</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Wali</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Fontana</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Levi</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Majumdar</surname>
							<given-names>APN</given-names>
						</name>
						<article-title>Cell cycle- and apoptosis-regulatory protein-1 is involved in
							apoptosis signaling by epidermal growth factor receptor</article-title>
						<source>J Biol Chem</source>
						<year>2006</year>
						<volume>281</volume>
						<fpage>13188</fpage>
						<lpage>13198</lpage>
						<pub-id pub-id-type="doi">10.1074/jbc.M512279200</pub-id>
						<pub-id pub-id-type="pmid">16543231</pub-id>
					</element-citation>
				</ref>
				<ref id="B5">
					<element-citation publication-type="journal">
						<name>
							<surname>Matsuoka</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Ballif</surname>
							<given-names>BA</given-names>
						</name>
						<name>
							<surname>Smogorzewska</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>McDonald</surname>
							<given-names>ER</given-names>
							<suffix>III</suffix>
						</name>
						<name>
							<surname>Hurov</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Luo</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Bakalarski</surname>
							<given-names>CE</given-names>
						</name>
						<name>
							<surname>Zhao</surname>
							<given-names>Z</given-names>
						</name>
						<name>
							<surname>Solimini</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Lerenthal</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Shiloh</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Gygi</surname>
							<given-names>SP</given-names>
						</name>
						<name>
							<surname>Elledge</surname>
							<given-names>SJ</given-names>
						</name>
						<article-title>ATM and ATR substrate analysis reveals extensive protein
							networks responsive to DNA damage</article-title>
						<source>Science</source>
						<year>2007</year>
						<volume>316</volume>
						<fpage>1160</fpage>
						<lpage>1166</lpage>
						<pub-id pub-id-type="doi">10.1126/science.1140321</pub-id>
						<pub-id pub-id-type="pmid">17525332</pub-id>
					</element-citation>
				</ref>
				<ref id="B6">
					<element-citation publication-type="journal">
						<name>
							<surname>Kim</surname>
							<given-names>JH</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>CK</given-names>
						</name>
						<name>
							<surname>Heo</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Roeder</surname>
							<given-names>RG</given-names>
						</name>
						<name>
							<surname>An</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Stallcup</surname>
							<given-names>MR</given-names>
						</name>
						<article-title>CCAR1, a key regulator of mediator complex recruitment to
							nuclear receptor transcription complexes</article-title>
						<source>Molecular Cell</source>
						<year>2008</year>
						<volume>31</volume>
						<fpage>510</fpage>
						<lpage>519</lpage>
						<pub-id pub-id-type="doi">10.1016/j.molcel.2008.08.001</pub-id>
						<pub-id pub-id-type="pmid">18722177</pub-id>
					</element-citation>
				</ref>
				<ref id="B7">
					<element-citation publication-type="journal">
						<name>
							<surname>Tzivion</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Shen</surname>
							<given-names>YH</given-names>
						</name>
						<name>
							<surname>Zhu</surname>
							<given-names>J</given-names>
						</name>
						<article-title>14-3-3 proteins; bringing new definitions to
							scaffolding</article-title>
						<source>Oncogene</source>
						<year>2001</year>
						<volume>20</volume>
						<fpage>6331</fpage>
						<lpage>6338</lpage>
						<pub-id pub-id-type="doi">10.1038/sj.onc.1204777</pub-id>
						<pub-id pub-id-type="pmid">11607836</pub-id>
					</element-citation>
				</ref>
				<ref id="B8">
					<element-citation publication-type="journal">
						<name>
							<surname>Kanai</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Marignani</surname>
							<given-names>PA</given-names>
						</name>
						<name>
							<surname>Sarbassova</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Yagi</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Hall</surname>
							<given-names>RA</given-names>
						</name>
						<name>
							<surname>Donowitz</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Hisaminato</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Fujiwara</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Ito</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Cantley</surname>
							<given-names>LC</given-names>
						</name>
						<name>
							<surname>Yaffe</surname>
							<given-names>MB</given-names>
						</name>
						<article-title>TAZ: a novel transcriptional co-activator regulated by
							interactions with 14-3-3 and PDZ domain proteins</article-title>
						<source>The EMBO J</source>
						<year>2000</year>
						<volume>24</volume>
						<fpage>6798</fpage>
						<lpage>6791</lpage>
					</element-citation>
				</ref>
				<ref id="B9">
					<element-citation publication-type="journal">
						<name>
							<surname>Hong</surname>
							<given-names>JH</given-names>
						</name>
						<name>
							<surname>Hwang</surname>
							<given-names>ES</given-names>
						</name>
						<name>
							<surname>McManus</surname>
							<given-names>MT</given-names>
						</name>
						<name>
							<surname>Amsterdam</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Tian</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Kalmukova</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Mueller</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Benjamin</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Spiegelman</surname>
							<given-names>BM</given-names>
						</name>
						<name>
							<surname>Sharp</surname>
							<given-names>PA</given-names>
						</name>
						<name>
							<surname>Hopkins</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Yaffe</surname>
							<given-names>MB</given-names>
						</name>
						<article-title>TAZ, a Transcriptional Modulator of Mesenchymal Stem Cell
							Differentiation</article-title>
						<source>Science</source>
						<year>2005</year>
						<volume>309</volume>
						<fpage>1074</fpage>
						<lpage>1078</lpage>
						<pub-id pub-id-type="doi">10.1126/science.1110955</pub-id>
						<pub-id pub-id-type="pmid">16099986</pub-id>
					</element-citation>
				</ref>
				<ref id="B10">
					<element-citation publication-type="journal">
						<name>
							<surname>Lei</surname>
							<given-names>QY</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Zhao</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Zha</surname>
							<given-names>ZY</given-names>
						</name>
						<name>
							<surname>Bai</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Pei</surname>
							<given-names>XH</given-names>
						</name>
						<name>
							<surname>Zhao</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Xiong</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Guan</surname>
							<given-names>KL</given-names>
						</name>
						<article-title>TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal
							Transition and Is Inhibited by the Hippo Pathway</article-title>
						<source>Mol Cell Biol</source>
						<year>2008</year>
						<volume>28</volume>
						<fpage>2426</fpage>
						<lpage>2436</lpage>
						<pub-id pub-id-type="doi">10.1128/MCB.01874-07</pub-id>
						<pub-id pub-id-type="pmid">18227151</pub-id>
					</element-citation>
				</ref>
				<ref id="B11">
					<element-citation publication-type="journal">
						<name>
							<surname>Chin</surname>
							<given-names>K-V</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>W-L</given-names>
						</name>
						<name>
							<surname>Ravtin</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Kita</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Reitman</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Vettori</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Cvijic</surname>
							<given-names>ME</given-names>
						</name>
						<name>
							<surname>Shin</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Iacono</surname>
							<given-names>L</given-names>
						</name>
						<article-title>Reinventing the wheel of cyclic AMP: Novel mechanisms of cAMP
							signaling</article-title>
						<source>Ann NY Acad Sci</source>
						<year>2002</year>
						<volume>968</volume>
						<fpage>49</fpage>
						<lpage>64</lpage>
						<pub-id pub-id-type="doi">10.1111/j.1749-6632.2002.tb04326.x</pub-id>
						<pub-id pub-id-type="pmid">12119267</pub-id>
					</element-citation>
				</ref>
				<ref id="B12">
					<element-citation publication-type="journal">
						<name>
							<surname>Engh</surname>
							<given-names>RA</given-names>
						</name>
						<name>
							<surname>Girod</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Kinzel</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Huber</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Bossemeyer</surname>
							<given-names>D</given-names>
						</name>
						<article-title>Crystal structures of catalytic subunit of cAMP-dependent
							protein kinase in complex with isoquinolinesulfonyl protein kinase
							inhibitors H7, H8, and H89. Structural implications for
							selectivity</article-title>
						<source>J Biol Chem</source>
						<year>1996</year>
						<volume>271</volume>
						<fpage>26157</fpage>
						<lpage>26164</lpage>
						<pub-id pub-id-type="doi">10.1074/jbc.271.42.26157</pub-id>
						<pub-id pub-id-type="pmid">8824261</pub-id>
					</element-citation>
				</ref>
				<ref id="B13">
					<element-citation publication-type="journal">
						<name>
							<surname>Taylor</surname>
							<given-names>SS</given-names>
						</name>
						<name>
							<surname>Buechler</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Yonemoto</surname>
							<given-names>W</given-names>
						</name>
						<article-title>cAMP-dependent protein kinase: framework for a diverse family
							of regulatory enzymes</article-title>
						<source>Annu Rev Biochem</source>
						<year>1990</year>
						<volume>59</volume>
						<fpage>971</fpage>
						<lpage>1005</lpage>
						<pub-id pub-id-type="doi">10.1146/annurev.bi.59.070190.004543</pub-id>
						<pub-id pub-id-type="pmid">2165385</pub-id>
					</element-citation>
				</ref>
				<ref id="B14">
					<element-citation publication-type="journal">
						<name>
							<surname>Murray</surname>
							<given-names>AJ</given-names>
						</name>
						<article-title>Pharmacological PKA inhibition: All may not be what it
							seems</article-title>
						<source>Sci Signal</source>
						<year>2008</year>
						<volume>1</volume>
						<fpage>Re4</fpage>
						<pub-id pub-id-type="doi">10.1126/scisignal.122re4</pub-id>
						<pub-id pub-id-type="pmid">18523239</pub-id>
					</element-citation>
				</ref>
				<ref id="B15">
					<element-citation publication-type="journal">
						<name>
							<surname>Tinnikov</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Yeung</surname>
							<given-names>KT</given-names>
						</name>
						<name>
							<surname>Das</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Samuels</surname>
							<given-names>HH</given-names>
						</name>
						<article-title>Identification of a novel pathway that selectively modulates
							apoptosis of breast cancer cells</article-title>
						<source>Cancer Res</source>
						<year>2009</year>
						<volume>69</volume>
						<fpage>1375</fpage>
						<lpage>1382</lpage>
						<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2896</pub-id>
						<pub-id pub-id-type="pmid">19190336</pub-id>
					</element-citation>
				</ref>
				<ref id="B16">
					<element-citation publication-type="book">
						<name>
							<surname>Beausoleil</surname>
							<given-names>SA</given-names>
						</name>
						<name>
							<surname>Jedrychowski</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Schwartz</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Elias</surname>
							<given-names>JE</given-names>
						</name>
						<name>
							<surname>Villen</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Cohn</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Cantley</surname>
							<given-names>LC</given-names>
						</name>
						<name>
							<surname>Gygi</surname>
							<given-names>SP</given-names>
						</name>
						<article-title>Large-scale characterization of HeLa cell nuclear
							phosphoproteins</article-title>
						<source>Proc Natl Acad Sci</source>
						<year>2004</year>
						<volume>101</volume>
						<publisher-name>USA</publisher-name>
						<fpage>12130</fpage>
						<lpage>12135</lpage>
						<pub-id pub-id-type="doi">10.1073/pnas.0404720101</pub-id>
						<pub-id pub-id-type="pmid">15302935</pub-id>
					</element-citation>
				</ref>
				<ref id="B17">
					<element-citation publication-type="journal">
						<name>
							<surname>Combet</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Blanchet</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Geourjon</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Deleage</surname>
							<given-names>G</given-names>
						</name>
						<article-title>NPS@: network protein sequence analysis</article-title>
						<source>Trends Biochem Sci</source>
						<year>2000</year>
						<volume>25</volume>
						<issue>3</issue>
						<fpage>147</fpage>
						<lpage>150</lpage>
						<pub-id pub-id-type="doi">10.1016/S0968-0004(99)01540-6</pub-id>
						<pub-id pub-id-type="pmid">10694887</pub-id>
					</element-citation>
				</ref>
				<ref id="B18">
					<element-citation publication-type="journal">
						<name>
							<surname>Ramana</surname>
							<given-names>CV</given-names>
						</name>
						<name>
							<surname>Grammatikakis</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Chernov</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Nguyen</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Goh</surname>
							<given-names>KC</given-names>
						</name>
						<name>
							<surname>Williams</surname>
							<given-names>BRG</given-names>
						</name>
						<name>
							<surname>Stark</surname>
							<given-names>GR</given-names>
						</name>
						<article-title>Regulation of c-myc expression by IFN-( through
							Stat1-dependent and -independent pathways</article-title>
						<source>The EMBO Journal</source>
						<year>2000</year>
						<volume>19</volume>
						<fpage>263</fpage>
						<lpage>272</lpage>
						<pub-id pub-id-type="doi">10.1093/emboj/19.2.263</pub-id>
						<pub-id pub-id-type="pmid">10637230</pub-id>
					</element-citation>
				</ref>
				<ref id="B19">
					<element-citation publication-type="journal">
						<name>
							<surname>Zhang</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Wali</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Ramana</surname>
							<given-names>CV</given-names>
						</name>
						<name>
							<surname>Rishi</surname>
							<given-names>AK</given-names>
						</name>
						<article-title>Cell growth inhibition by Okadaic acid involves Gut-enriched
							Kruppel-like factor-mediated enhanced expression of
							c-Myc</article-title>
						<source>Cancer Research</source>
						<year>2007</year>
						<volume>67</volume>
						<issue>21</issue>
						<fpage>10198</fpage>
						<lpage>206</lpage>
						<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2505</pub-id>
						<pub-id pub-id-type="pmid">17974960</pub-id>
					</element-citation>
				</ref>
				<ref id="B20">
					<element-citation publication-type="journal">
						<name>
							<surname>Zha</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Harada</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Jockel</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Korsmeyer</surname>
							<given-names>SJ</given-names>
						</name>
						<article-title>Serine phosphorylation of death agonist BAD in response to
							survival factor results in binding to 14-3-3 not
							BCL-X(L)</article-title>
						<source>Cell</source>
						<year>1996</year>
						<volume>87</volume>
						<fpage>619</fpage>
						<lpage>628</lpage>
						<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81382-3</pub-id>
						<pub-id pub-id-type="pmid">8929531</pub-id>
					</element-citation>
				</ref>
				<ref id="B21">
					<element-citation publication-type="journal">
						<name>
							<surname>Datta</surname>
							<given-names>SR</given-names>
						</name>
						<name>
							<surname>Dudek</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Tao</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Masters</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Fu</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Gotoh</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Greenberg</surname>
							<given-names>ME</given-names>
						</name>
						<article-title>Akt phosphorylation of BAD couples survival signals to the
							cell-intrinsic death machinery</article-title>
						<source>Cell</source>
						<year>1997</year>
						<volume>91</volume>
						<issue>2</issue>
						<fpage>231</fpage>
						<lpage>41</lpage>
						<pub-id pub-id-type="doi">10.1016/S0092-8674(00)80405-5</pub-id>
						<pub-id pub-id-type="pmid">9346240</pub-id>
					</element-citation>
				</ref>
				<ref id="B22">
					<element-citation publication-type="journal">
						<name>
							<surname>Marcu</surname>
							<given-names>KB</given-names>
						</name>
						<name>
							<surname>Bossone</surname>
							<given-names>SA</given-names>
						</name>
						<name>
							<surname>Patel</surname>
							<given-names>AJ</given-names>
						</name>
						<article-title>myc function and regulation</article-title>
						<source>Annu Rev Biochem</source>
						<year>1992</year>
						<volume>61</volume>
						<fpage>809</fpage>
						<lpage>860</lpage>
						<pub-id pub-id-type="doi">10.1146/annurev.bi.61.070192.004113</pub-id>
						<pub-id pub-id-type="pmid">1497324</pub-id>
					</element-citation>
				</ref>
				<ref id="B23">
					<element-citation publication-type="journal">
						<name>
							<surname>Iavarone</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Catania</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Marinissen</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Visconti</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Acunzo</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Tarantino</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Carlomagno</surname>
							<given-names>MS</given-names>
						</name>
						<name>
							<surname>Bruni</surname>
							<given-names>CB</given-names>
						</name>
						<name>
							<surname>Gutkind</surname>
							<given-names>JS</given-names>
						</name>
						<name>
							<surname>Chiariello</surname>
							<given-names>M</given-names>
						</name>
						<article-title>The Platelet-derived Growth Factor Controls c-<italic>myc
							</italic>Expression through a JNK- and AP-1-dependent Signaling
							Pathway</article-title>
						<source>J Biol Chem</source>
						<year>2003</year>
						<volume>278</volume>
						<fpage>50024</fpage>
						<lpage>50030</lpage>
						<pub-id pub-id-type="doi">10.1074/jbc.M308617200</pub-id>
						<pub-id pub-id-type="pmid">14523011</pub-id>
					</element-citation>
				</ref>
				<ref id="B24">
					<element-citation publication-type="journal">
						<name>
							<surname>Chiariello</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Marinissen</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Gutkind</surname>
							<given-names>JS</given-names>
						</name>
						<article-title>Regulation of c-myc expression by PDGF through Rho
							GTPases</article-title>
						<source>Nature Cell Biol</source>
						<year>2001</year>
						<volume>3</volume>
						<fpage>580</fpage>
						<lpage>586</lpage>
						<pub-id pub-id-type="doi">10.1038/35078555</pub-id>
						<pub-id pub-id-type="pmid">11389443</pub-id>
					</element-citation>
				</ref>
				<ref id="B25">
					<element-citation publication-type="other">
						<name>
							<surname>Ausubel</surname>
							<given-names>FM</given-names>
						</name>
						<name>
							<surname>Brent</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Kingston</surname>
							<given-names>RE</given-names>
						</name>
						<name>
							<surname>Moore</surname>
							<given-names>DD</given-names>
						</name>
						<name>
							<surname>Seidman</surname>
							<given-names>JG</given-names>
						</name>
						<name>
							<surname>Smith</surname>
							<given-names>JG</given-names>
						</name>
						<name>
							<surname>Struhl</surname>
							<given-names>K</given-names>
						</name>
						<collab>Eds</collab>
						<article-title>Current protocols in molecular biology</article-title>
						<year>1990</year>
						<volume>2</volume>
					</element-citation>
				</ref>
			</ref-list>
		</back>
	</article>
</pmc-articleset>
